PharmExec Blog
Follow Us
RSS
Bookstore
Author Archives: Clark Herman
Drug Pipelines in Canada: Is There a Buyer for Future Innovation?
Last week, Canada’s National Prescription Drug Utilization Information System (NPDUIS), a federal-provincial fact-finding panel that works closely with the Patented Medicines Prices Review Board (PMPRB), issued its fourth New Drug Pipeline Monitor (NDPM) looking at drugs currently under development that may have an impact on future drug expenditures. The report is another example of how [...]
Posted in Global, IP, Market Access, Orphan Drugs, R&D, Regulatory, healthcare, pricing Tagged Bernard Lachapelle, Canada, Health Canada, NPDUIS, pipeline, PMPRB Leave a comment
Physicians in ACOs Dare Pharma to Step up Its Game
Pharma, according to physicians currently embedded within Accountable Care Organizations (ACOs), is not living up to its potential. A survey conducted by Oliver Wyman has most of its 200 respondents saying the industry could play a more active role with value-based healthcare providers in helping to deliver better care at a lower cost, but it [...]
Posted in Strategy, healthcare Tagged Accountable Care Organization, ACOs, commercial health, physicians, quality of care Leave a comment
Mapping Opportunities with the Non-Physician Prescriber
They write 92% of their prescriptions without consulting a physician and are often the first provider a patient sees, and yet nurse practitioners, physician’s assistants and other non-physician prescribers (NPPs) are still somehow overlooked by pharma as an opportunity to drive sales. A GSW Worldwide report titled The non-physician prescriber will see you now points [...]
Posted in Advertising, Marketing, Patient Communication, Sales, Strategy, compliance, healthcare, patient compliance, patient education Tagged Aetna, GSW Worldwide, non-physician prescriber, nurse practitioner, physician's assistant, physicians, primary care physicians, Professional Marketing, professional sales, report, sales representatives, Sales Reps, Strategy Leave a comment
The FTC's Beef with Pay For Delay: What's the Fuss?
Yesterday, the Supreme Court heard arguments on the matter of pay-for-delay settlements between patent holders and generic firms. The Federal Trade Commission (FTC) hopes to overturn the 11th federal circuit’s ruling that such settlements are not anti-competitive on the grounds that these settlements amount to a restraint of trade under the commerce clause of the [...]
Posted in IP, Legal, Market Access, Regulatory Tagged Actavis, Andro-Gel, FTC, Hatch-Waxman, Supreme Court 1 Comment
A Global Consensus: Oncologists Spooked By Health Reforms